Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?

Sprengers and colleagues conclude that Bumetanide does not attenuate autism spectrum disorder (ASD) despite a nominally significant treatment effect in repetitive behaviors (RBS) which is a core-symptom of ASD but was defined as a secondary measure in this trial.1 Four earlier studies performed by three independent institutes, including two that are not referred to2,3 by Sprengers and colleagues, tested a total of 169 children -vs 122 placebo- have shown a significant amelioration of ASD symptomatology.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Authors: Tags: Letter to the Editor Source Type: research